Alpharma rejects higher King bid; Wyeth hikes quarterly dividend;

> Alpharma has again rebuffed King Pharmaceuticals, which sweetened its buyout offer to $37 from $33, and says it's continuing to look for other alternatives to "maximize shareholder value." Report

> Wyeth's board of directors boosted the drug developer's quarterly dividend by 7.1 percent, citing the company's cash position, receding litigation payments and growth prospects. Report

> President Bush's AIDS drug program has cut Ranbaxy drugs from the mix after the FDA halted imports of the Indian generics makers products. Report

> Four years after Boston bucked federal regulators to offer low-cost Canadian prescription drugs to employees and retirees, the program has fizzled, never having attracted more than a few dozen participants. Report

> Ligand Pharmaceuticals said it planned to acquire New Jersey biotechnology drugmaker Pharmacopeia for up to $70 million in a stock transaction. Ligand release

> Merck said Europe's Committee for Medicinal Products for Human Use (CHMP) recommended approval for Kuvan (sapropterin dihydrochloride) as an oral treatment for hyperphenylalaninemia. Merck Serono release

> Sanofi-Aventis has added to its campaign for sleeping pill Ambien CR with an online video game called "Silence Your Rooster." Report

> Bad news for NPS Pharmaceuticals: the company announced late Thursday that its partner GlaxoSmithKline would abandon a Phase II study of Ronacalaret, an osteoporosis drug. Report

> Merck has signed an agreement with Japan Tobacco to develop and commercialize JTT-305, an investigational oral osteoanabolic drug. Report

> France-based Novagali Pharma has raised €15 million in a new financing round. Report

> Citing "historic instability in the market," Fluidigm announced today that it has withdrawn its registration statement for its IPO. Report

> Emergent BioSolutions has inked a three-year, $29.7 million deal with Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). Report

> After quietly backing the small Canadian vaccine developer Medicago, the giant tobacco company Philip Morris has stepped up to grab a majority interest in the company. Report

And Finally... Good news for scientists and researchers: despite a number of layoffs and hiring freezes, there is still high demand in the biotech industry. And human resources managers are going above and beyond to attract good talent. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.